AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$RNXT

RenovoRx Inc (RNXT) (Q3 2026) Earnings Call Highlights: Record Revenue, Expanding

RenovoRx Inc (RNXT) reported Q3 2026 record revenue of $1.07M, up 17% sequentially. CEO Sean Bagai discussed potential impacts of Razin-Q approval on pancreatic cancer treatment and commercialization plans. The company has 26 active commercial centers, with a target of 36 by year-end. Phase III TIGER-PACT trial data is expected in H2 2027. Gross margin was 82%, and cash position is $10.4M. Full-year 2026 revenue guidance remains $3.75M-$4.25M.

Original reporting
finance.yahoo.com
Published Nov 6, 2026, 7:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 7:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
RenovoRx Inc (RNXT) (Q3 2026) Earnings Call Highlights: Record Revenue, Expanding — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RNXTNeutralMed
01

Why it matters

The earnings call provides the first public financial snapshot, setting expectations for future commercial rollout.

02

Market read

Micro‑cap biotech earnings with modest beat; may trigger short‑term trading interest but limited long‑term impact.

03

What to watch

Cash runway only into H2 2027; reliance on a single device platform adds execution risk.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

RenovoRx provides the RenovoCath device for localized chemotherapy (TAMP) in pancreatic cancer.

Company-level read

Ticker impact

$RNXTNeutralMedium confidence
Context

Q3 2026 earnings call disclosed record $1.07M revenue, 17% sequential growth and full-year guidance of $3.75‑$4.25M.

Expected impact

potential modest upside as investors price in revenue beat and guidance

Evidence & confidence

New earnings numbers and guidance are primary information, but the absolute scale is small, limiting large moves.

Market effects

Sector

Highlights progress in pancreatic cancer device therapy, may draw attention to similar biotech firms.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Low global impact given company size and niche focus.

Counterpoint

What could challenge this read

Revenue growth may be unsustainable without broader adoption; caution on over‑optimism.

Key entities

  • Executive
    Sean Bagai

    CEO who discussed trial data and commercial strategy.

  • Executive
    Mark Voll

    CFO who presented financial results and cash position.

Read at source← All news

Related articles

$RNXTMed

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel…

RenovoRx, Inc. (RNXT) filed an SEC Form 8-K — Results of Operations and Financial Condition. RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion

SEC EDGAR 8-K
$RNXTMedAI 8/10

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx (Nasdaq: RNXT) announced the first patient has enrolled in the PRISM-TAMP trial, evaluating its TAMP platform for borderline resectable pancreatic cancer. The trial, sponsored by the University of Vermont, aims to assess tumor regression and safety. RenovoRx reported $1.1M in 2025 RenovoCath sales and $909K in Q2 2026. The company expects topline data from its Phase III TIGeR-PaC trial in late 2027.

globenewswire.com
$RNXTMedAI 8/10

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) announced a peer-reviewed publication in Case Reports in Oncology. The study, led by researchers at Hackensack Meridian Health, showed promising results for two locally advanced pancreatic cancer patients treated with the company's TAMP platform and RenovoCath device. The patients experienced tumor responses and reductions in CA 19-9 markers.

globenewswire.com
$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

rttnews.com